Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jan;17(1):53-64.
doi: 10.1007/s11739-021-02750-8. Epub 2021 May 10.

Characteristic of IgA and IgG antibody response to SARS-CoV-2 infection in an Italian referral COVID-19 Hospital

Affiliations

Characteristic of IgA and IgG antibody response to SARS-CoV-2 infection in an Italian referral COVID-19 Hospital

Annamaria Carnicelli et al. Intern Emerg Med. 2022 Jan.

Abstract

Introduction: Antibody response plays a fundamental role in the natural history of infectious disease. A better understanding of the immune response in patients with SARS-CoV-2 infection could be important for identifying patients at greater risk of developing a more severe form of disease and with a worse prognosis.

Methods: We performed a cross-sectional analysis to determine the presence and the levels of both anti-SARS-CoV-2 IgG and IgA in a cohort of hospitalized patients with confirmed infection at different times in the natural history of the disease. Patients enrolled when admitted at the emergency department were prospectively followed up during hospital stay.

Results: Overall, 131 patients were considered with a total of 237 samples processed. Cross-sectional analysis showed that seroconversion for IgA seems to occur between days 6 and 15, while IgG response seems to occur slightly later, peaking at day 20 after symptoms onset. Both IgA and IgG were maintained beyond 2 months. Severe patients showed a higher IgA response compared with mild patients when analyzing optical density (8.3 versus 5.6, p < 0.001). Prospective analysis conducted on 55 patients confirmed that IgA appear slightly earlier than IgG. After stratifying for the severity of disease, both the IgA and IgG responses were more vigorous in severe cases. Moreover, while IgG tended to stabilize, there was a relevant decline after the first month of IgA levels in mild cases.

Conclusion: IgA and IgG antibody response is closely related, although seroconversion for IgA occurs earlier. Both IgA and IgG are maintained beyond 2 months. Severe patients showed a more vigorous IgA and IgG response. IgA levels seem to decline after 1 month since the onset of symptoms in mild cases. Our results should be interpreted with cautions due to several limitations in our study, mainly the small number of cases, lack of data on viral load and clinical setting.

Keywords: Antibody; COVID-19; IgA; IgG; SARS-CoV-2.

PubMed Disclaimer

Conflict of interest statement

The authors have no funding or conflicts of interest to disclose.

Figures

Fig. 1
Fig. 1
Positivity rates shows a more abrupt increase for IgA at the 11–15 time frame, while there is a more smoldered trend for IgG. Each bar represents the difference in positivity rates between each time frame and the previous one
Fig. 2
Fig. 2
Optical density in time for all samples divided by Ig class. LOESS curve interpolation is shown. Shaded areas represent confidence intervals around LOESS curves
Fig. 3
Fig. 3
Boxplot showing difference in optical density between severe and mild patients both for IgA and IgG. All positive sample were included in the plot, with multiple samples per each patient
Fig. 4
Fig. 4
a Density versus time plot for different Ig class for prospectively enrolled patients. b Density versus time plot for different Ig class and for different severity of disease in prospectively enrolled patients. LOESS curve interpolation is shown. Shaded areas represent confidence intervals around LOESS curves

References

    1. Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382:727–733. doi: 10.1056/NEJMoa2001017. - DOI - PMC - PubMed
    1. Lu R, Zhao X, Li J, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet (London, England) 2020;395:565–574. doi: 10.1016/S0140-6736(20)30251-8. - DOI - PMC - PubMed
    1. WHO (2020) WHO Director-General’s opening remarks at the media briefing on COVID-19—11 March 2020. https://www.who.int/dg/speeches/detail/who-director-general-s-opening-re.... Accessed 15 May 2020
    1. WHO https://covid19.who.int/
    1. Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China. JAMA. 2020;323:1239. doi: 10.1001/jama.2020.2648. - DOI - PubMed